CRISPR Therapeutics (CRSP) said Monday that preliminary data from an ongoing phase 1/2 trial of CTX112 in relapsed or refractory CD19-positive B-cell malignancies showed that the therapy was well tolerated and induced objective and complete responses at all dose levels.
Five out of the 12 treated patients have achieved responses lasting for more than six months, including one patient whose 6-month response was confirmed after the data cut-off date, according to the company.
"Preliminary data demonstrate that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol," the company said.
CRISPR also said that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to CTX112 for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.
Price: 50.78, Change: -1.55, Percent Change: -2.97
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。